Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Gynecology

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 58 articles: HTML format

Single Articles

March 2023
1. ABE M, Shoji T, Chiba Y, Takatori E, et al
   Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
   Anticancer Res. 2023;43:1265-1272.
   PubMed     Abstract available
   
   
   February 2023
2. TAKIMOTO Y, Tsubamoto H, Taniguchi R, Sakata K, et al
   Itraconazole Repolarizes Tumor-associated Macrophages and Suppresses Cervical Cancer Cell Growth.
   Anticancer Res. 2023;43:569-580.
   PubMed     Abstract available
   
   
   
3. MARTIN-SALAMANCA B, Erasun D, Llorca J, Schneider J, et al
   Ki67 and E-cadherin Are Independent Predictors of Long-term Survival in Endometrial Carcinoma.
   Anticancer Res. 2023;43:683-687.
   PubMed     Abstract available
   
   
   
4. BOURIEN H, Lefevre LB, Mouret-Reynier MA, Asselain B, et al
   Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
   Anticancer Res. 2023;43:653-662.
   PubMed     Abstract available
   
   
   January 2023
5. PISTOLESI S, Fanelli GN, Giudice F, Garbini F, et al
   Cervical Adenocarcinoma: A Still Under-investigated Malignancy.
   Anticancer Res. 2023;43:53-58.
   PubMed     Abstract available
   
   
   
6. LALISCIA C, Gadducci A, Coccia N, Mattioni R, et al
   Lymph-vascular Space Involvement and/or p53 Overexpression Correlated With the Clinical Outcome of Early-stage Endometrial Cancer Patients Treated With Adjuvant Vaginal Brachytherapy.
   Anticancer Res. 2023;43:149-156.
   PubMed     Abstract available
   
   
   December 2022
7. RALSER DJ, Condic M, Egger E, Koensgen D, et al
   Evaluation of the Diagnostic Potential of Circulating MicroRNAs miR-1 and miR-21 in Patients With Ovarian Cancer.
   Anticancer Res. 2022;42:5839-5845.
   PubMed     Abstract available
   
   
   November 2022
8. BIENKOWSKA-TOKARCZYK A, Manda-Handzlik A, Gawrychowski K, Demkow U, et al
   The Activity of Vitamin C Against Ovarian Cancer Cells Is Enhanced by Hyperthermia.
   Anticancer Res. 2022;42:5365-5383.
   PubMed     Abstract available
   
   
   October 2022
9. EGGER E, Merker F, Ralser DJ, Condic M, et al
   Tumor Load Matters - the Peritoneal Cancer Index in Patients With High-grade Serous Ovarian Cancer.
   Anticancer Res. 2022;42:4825-4831.
   PubMed     Abstract available
   
   
   
10. KISE S, Arakaki Y, Kudaka W, Ariga T, et al
    Sarcopenia Is an Independent Prognostic Factor for Squamous Cell Carcinoma of the Cervix Treated With Concurrent Chemoradiotherapy.
    Anticancer Res. 2022;42:4887-4893.
    PubMed     Abstract available
    
    
    
11. KIM JY, Park H, Lee DW, Kim MJ, et al
    Prognostic Significance of Clinical Factors Including BRCA Mutation in Epithelial Ovarian, Peritoneal, Fallopian Tube Cancer.
    Anticancer Res. 2022;42:4945-4954.
    PubMed     Abstract available
    
    
    
12. LEE J, Hong DG
    Comparison of Survival Outcomes Based on Pre-treatment Pleural Effusion in Advanced Epithelial Ovarian Cancer.
    Anticancer Res. 2022;42:4937-4943.
    PubMed     Abstract available
    
    
    
13. GADDUCCI A, Cosio S, Lippolis PV
    Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Anticancer Res. 2022;42:4659-4665.
    PubMed     Abstract available
    
    
    September 2022
14. LEE Y, Bae H, Kim HS
    Endocervical Adenocarcinoma: Comprehensive Histological Review and Re-classification of 123 Consecutive Cases According to the Updated World Health Organization Classification of Female Genital Tumors.
    Anticancer Res. 2022;42:4627-4639.
    PubMed     Abstract available
    
    
    
15. TATSUKI S, Shoji T, Abe M, Tomabechi H, et al
    Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2022;42:4603-4610.
    PubMed     Abstract available
    
    
    
16. OKAMOTO K, Nakamura K, Haraga J, Masuyama H, et al
    Molecular Characteristics of Metastatic Lesions Have Superior Prognostic Impact on Endometrial Cancer.
    Anticancer Res. 2022;42:4535-4543.
    PubMed     Abstract available
    
    
    
17. GADDUCCI A, Cosio S
    Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research.
    Anticancer Res. 2022;42:4207-4216.
    PubMed     Abstract available
    
    
    
18. ZEITLER C, Fuderer L, Schmitz K, Arora R, et al
    Pheochromocytoma Turned Malignant During Pregnancy in a Patient With Neurofibromatosis Type I - A Case Report and Systematic Review of the Current Literature.
    Anticancer Res. 2022;42:4647-4656.
    PubMed     Abstract available
    
    
    
19. FERINI G, Valenti V, Viola A, Umana GE, et al
    First-ever Clinical Experience With Magnetic Resonance-based Lattice Radiotherapy for Treating Bulky Gynecological Tumors.
    Anticancer Res. 2022;42:4641-4646.
    PubMed     Abstract available
    
    
    August 2022
20. YOTSUMOTO F, Sanui A, Ito T, Miyahara D, et al
    Cumulative Summation Analysis of Learning Curve for Robotic-assisted Hysterectomy in Patients With Gynecologic Tumors.
    Anticancer Res. 2022;42:4111-4117.
    PubMed     Abstract available
    
    
    
21. OGATA N, Toh U, Sudou T, Ogata S, et al
    Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
    Anticancer Res. 2022;42:4139-4143.
    PubMed     Abstract available
    
    
    
22. YOKOYAMA Y, Kubo-Kaneda M, Sunada K, Teishikata Y, et al
    Adverse Events Associated With Long-term Treatment of Epithelial Ovarian Cancer With Bevacizumab and Chemotherapy.
    Anticancer Res. 2022;42:4165-4171.
    PubMed     Abstract available
    
    
    July 2022
23. VEYSSIERE H, Aldarazi G, Molnar I, Durando X, et al
    Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy.
    Anticancer Res. 2022;42:3583-3594.
    PubMed     Abstract available
    
    
    
24. RAJHA A, Piso P, Halmy L, Panczel I, et al
    Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Anticancer Res. 2022;42:3681-3692.
    PubMed     Abstract available
    
    
    
25. IMAMURA A, Oike T, Sato H, Yoshimoto Y, et al
    Comparative Analysis of the Antitumor Immune Profiles of Paired Radiotherapy-naive and Radiotherapy-treated Cervical Cancer Tissues.
    Anticancer Res. 2022;42:3341-3348.
    PubMed     Abstract available
    
    
    
26. TATE S, Nishikimi K, Matsuoka A, Otsuka S, et al
    Highly Aggressive Surgery Benefits in Patients With Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:3707-3716.
    PubMed     Abstract available
    
    
    June 2022
27. GIVENS NT, Zhao L, Zhu Z, Lequio M, et al
    Mangosteen Inhibits Growth and Survival of Cervical Cancer Cells.
    Anticancer Res. 2022;42:2903-2909.
    PubMed     Abstract available
    
    
    
28. UNO A, Yamamoto S, Iihara H, Fujii H, et al
    Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.
    Anticancer Res. 2022;42:3117-3123.
    PubMed     Abstract available
    
    
    
29. OOYAMA T, Shimoji Y, Nakasone T, Arakaki Y, et al
    Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent Ovarian Cancer.
    Anticancer Res. 2022;42:3017-3022.
    PubMed     Abstract available
    
    
    May 2022
30. TATE S, Nishikimi K, Matsuoka A, Otsuka S, et al
    Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer.
    Anticancer Res. 2022;42:2637-2644.
    PubMed     Abstract available
    
    
    
31. ASP M, Malander S, Bengtsson J, Sartor H, et al
    Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:2541-2551.
    PubMed     Abstract available
    
    
    
32. MAGKANA M, Mentzelopoulou P, Magkana E, Pampanos A, et al
    p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening.
    Anticancer Res. 2022;42:2599-2606.
    PubMed     Abstract available
    
    
    April 2022
33. AN J, Oh HE, Kim H, Lee JH, et al
    Significance of Altered Fatty Acid Transporter Expressions in Uterine Cervical Cancer and Its Precursor Lesions.
    Anticancer Res. 2022;42:2131-2137.
    PubMed     Abstract available
    
    
    
34. GADDUCCI A, Cosio S, Landoni F, Lissoni AA, et al
    Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
    Anticancer Res. 2022;42:2017-2022.
    PubMed     Abstract available
    
    
    
35. MITSOPOULOS V, Innamaa A, Lippiatt J, Collins S, et al
    Differences in Patterns of Recurrence Between Primary and Interval Debulking Surgery for Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:2003-2008.
    PubMed     Abstract available
    
    
    
36. ADDLEY S, McGowan M, Asher V, Bali A, et al
    Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery.
    Anticancer Res. 2022;42:1979-1986.
    PubMed     Abstract available
    
    
    
37. SHORAKA M, Carbajal-Mamani SL, Dideban B, Zarrinpar A, et al
    Clinical Utility and Cost of Postoperative Hemoglobin Level Testing Following Robotic-assisted Hysterectomy for Endometrial Cancer.
    Anticancer Res. 2022;42:1893-1898.
    PubMed     Abstract available
    
    
    
38. ABOBAKER S, Kulbe H, Taube ET, Darb-Esfahani S, et al
    Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer.
    Anticancer Res. 2022;42:1739-1747.
    PubMed     Abstract available
    
    
    
39. OHASHI K, Li TS, Miura S, Hasegawa Y, et al
    Biological Differences Between Ovarian Cancer-associated Fibroblasts and Contralateral Normal Ovary-derived Mesenchymal Stem Cells.
    Anticancer Res. 2022;42:1729-1737.
    PubMed     Abstract available
    
    
    March 2022
40. HECKING T, Thiesler T, Halbe J, Otten L, et al
    Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
    Anticancer Res. 2022;42:1367-1376.
    PubMed     Abstract available
    
    
    February 2022
41. DELRUE C, Vanwalleghem L, Paepe P, Trappen PV, et al
    Stratified Mucin-producing Intraepithelial Lesions of the Cervix: Clinical Diversity of Cases and Literature Review.
    Anticancer Res. 2022;42:1175-1180.
    PubMed     Abstract available
    
    
    
42. MATSUDA R, Sato F, Kotsugi M, Morimoto T, et al
    Awake Surgery for Local Recurrence of Brain Metastasis in the Precentral Gyrus After Fractionated Stereotactic Radiotherapy: A Technical Case Report.
    Anticancer Res. 2022;42:1151-1155.
    PubMed     Abstract available
    
    
    
43. SHIBATA N, Kawakami K, Hisanori S, Kobayashi K, et al
    Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy.
    Anticancer Res. 2022;42:1091-1097.
    PubMed     Abstract available
    
    
    
44. ALEXOPOULOS A, Karanikiotis C, Ardavanis A, Boukovinas I, et al
    Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" s
    Anticancer Res. 2022;42:1031-1041.
    PubMed     Abstract available
    
    
    
45. DOBILAS A, Thalin C, Wallen H, Borgfeldt C, et al
    Circulating Markers of Neutrophil Extracellular Traps (NETs) in Patients With Ovarian Tumors.
    Anticancer Res. 2022;42:965-971.
    PubMed     Abstract available
    
    
    
46. GADDUCCI A, Simonetti E, Mezzapesa F, Cosio S, et al
    Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study.
    Anticancer Res. 2022;42:947-954.
    PubMed     Abstract available
    
    
    January 2022
47. HOSOYA S, Ueda K, Odajima S, Ogawa K, et al
    Scoring Systems of Peritoneal Dissemination for the Prediction of Operative Completeness in Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:115-124.
    PubMed     Abstract available
    
    
    
48. CARDENAS-GOICOECHEA J, Wang YU, Lee JH, Shoraka M, et al
    Survival After Minimally Invasive Surgery in Older Women With Endometrial Carcinoma.
    Anticancer Res. 2022;42:75-85.
    PubMed     Abstract available
    
    
    
49. ACS M, Piso P, Prader S
    Current Status of Metastatic Cardiophrenic Lymph Nodes (CPLNs) in Patients With Ovarian Cancer: A Review.
    Anticancer Res. 2022;42:13-24.
    PubMed     Abstract available
    
    
    
50. BISKUP E, Wils RS, Hogdall C, Hogdall E, et al
    Prospects of Improving Early Ovarian Cancer Diagnosis Using Cervical Cell Swabs.
    Anticancer Res. 2022;42:1-12.
    PubMed     Abstract available
    
    
    
51. LEE J, Kim JM, Lee YH, Chong GO, et al
    Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer.
    Anticancer Res. 2022;42:349-353.
    PubMed     Abstract available
    
    
    
52. LEE EJ, Park SJ, Lee J, Mun J, et al
    The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study.
    Anticancer Res. 2022;42:363-371.
    PubMed     Abstract available
    
    
    December 2021
53. LEE J, Kim JM, Lee YH, Chong GO, et al
    Applicability of the Histoculture Drug Response Assay to Predict Platinum Sensitivity and Prognosis in Ovarian Cancer.
    Anticancer Res. 2021;41:6287-6292.
    PubMed     Abstract available
    
    
    
54. CHECK JH, Check D
    New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor.
    Anticancer Res. 2021;41:5873-5880.
    PubMed     Abstract available
    
    
    November 2021
55. ISONO R, Tsubamoto H, Ueda T, Takimoto Y, et al
    Itraconazole Inhibits Intracellular Cholesterol Trafficking and Decreases Phosphatidylserine Level in Cervical Cancer Cells.
    Anticancer Res. 2021;41:5477-5480.
    PubMed     Abstract available
    
    
    October 2021
56. NOSAKA K, Suzuki S, Yoshikawa T, Shimomura M, et al
    Heat Shock Protein 105 as an Immunotherapeutic Target for Patients With Cervical Cancer.
    Anticancer Res. 2021;41:4741-4751.
    PubMed     Abstract available
    
    
    
57. GADDUCCI A, Cosio S
    Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review.
    Anticancer Res. 2021;41:4673-4685.
    PubMed     Abstract available
    
    
    
58. LUENGAS-WUERZINGER V, Rawert F, CLAssEN-VON Spee S, Baransi S, et al
    Role of the Cardiophrenic Lymph Node Status After Neoadjuvant Chemotherapy in Primary Advanced Ovarian Cancer.
    Anticancer Res. 2021;41:5025-5031.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: